The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | alloHCT: HLA-matched unrelated vs HLA-identical sibling donor for MDS
Guru Subramanian Guru Murthy, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the findings of a retrospective study investigating whether allogeneic hematopoietic cell transplantation (alloHCT) with younger HLA-matched unrelated donors is associated with superior disease-free survival (DFS) for patients with myelodysplastic syndromes (MDS) when compared with older HLA-identical sibling donors. The study, which analyzed data from 1761 patients, found superior DFS for MDS patients undergoing alloHCT from younger HLA-matched unrelated donors compared to older HLA-identical sibling donors. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
